When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity, Mizuho notes ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

B. Riley views the selloff in shares of Viking Therapeutics (VKTX) following VK2735 oral weight loss data as overdone. The pullback indicates the ...

Viking Therapeutics ( (VKTX) ) has provided an announcement.

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:12 pm The Vanguard S&P 500 ETF closed at 588.15 Tuesday, down 0.5%.

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...